Literature DB >> 22198831

The patient's experience of gout: new insights to optimize management.

Nicola Dalbeth1, Karen Lindsay.   

Abstract

Despite the high prevalence of disease, gout management is frequently poor, with low patient adherence to urate-lowering therapy and attainment of recommended serum urate targets. Recent research has explored the patient's experience of gout, providing new understanding of the impact of disease. Pain is central to the patient's experience of gout. Poorly controlled gout leads to limitation of activities, reduced participation, and poor health-related quality of life. Although effective gout management with urate-lowering therapy improves many patient-reported outcomes in clinical trials, major gaps exist in patient understanding of disease and adherence to long-term urate-lowering therapy. Furthermore, a large mismatch in the perceptions of gout and its therapy exists between patients and health care practitioners. These issues may contribute to progressive and poorly controlled disease despite the availability of effective treatment. These findings provide potential pathways to improved clinical care of patients with gout. Work is now required to identify the optimal models of care for patients with gout that can be tested in clinical trials using outcome measures of relevance to individuals with this disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22198831     DOI: 10.1007/s11926-011-0228-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  29 in total

1.  Why illness perceptions matter.

Authors:  Keith J Petrie; John Weinman
Journal:  Clin Med (Lond)       Date:  2006 Nov-Dec       Impact factor: 2.659

2.  Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.

Authors:  Rachel Halpern; Reema R Mody; Mahesh J Fuldeore; Pankaj A Patel; Ted R Mikuls
Journal:  Curr Med Res Opin       Date:  2009-07       Impact factor: 2.580

3.  Patients and providers view gout differently: a qualitative study.

Authors:  Leslie R Harrold; Kathleen M Mazor; Sarah Velten; Ira S Ockene; Robert A Yood
Journal:  Chronic Illn       Date:  2010-07-30

4.  Patient-reported outcomes in chronic gout: a report from OMERACT 10.

Authors:  Jasvinder A Singh; Will J Taylor; Lee S Simon; Puja P Khanna; Lisa K Stamp; Fiona M McQueen; Tuhina Neogi; Angelo L Gaffo; Michael A Becker; Patricia A MacDonald; Omar Dabbous; Vibeke Strand; Nicola D Dalbeth; Daniel Aletaha; N Lawrence Edwards; H Ralph Schumacher
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

5.  The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach.

Authors:  Karen Lindsay; Peter Gow; Jane Vanderpyl; Phillip Logo; Nicola Dalbeth
Journal:  J Clin Rheumatol       Date:  2011-01       Impact factor: 3.517

6.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Authors:  John S Sundy; Herbert S B Baraf; Robert A Yood; N Lawrence Edwards; Sergio R Gutierrez-Urena; Edward L Treadwell; Janitzia Vázquez-Mellado; William B White; Peter E Lipsky; Zeb Horowitz; William Huang; Allan N Maroli; Royce W Waltrip; Steven A Hamburger; Michael A Becker
Journal:  JAMA       Date:  2011-08-17       Impact factor: 56.272

7.  National prevalence of gout derived from administrative health data in Aotearoa New Zealand.

Authors:  Doone Winnard; Craig Wright; William J Taylor; Gary Jackson; Leanne Te Karu; Peter J Gow; Bruce Arroll; Simon Thornley; Barry Gribben; Nicola Dalbeth
Journal:  Rheumatology (Oxford)       Date:  2012-01-16       Impact factor: 7.580

Review 8.  A roadmap for education to improve the quality of care in gout.

Authors:  Alexis R Ogdie; Susan Hoch; Jonathan Dunham; Joan M Von Feldt
Journal:  Curr Opin Rheumatol       Date:  2010-03       Impact factor: 5.006

9.  The dynamics of chronic gout treatment: medication gaps and return to therapy.

Authors:  Leslie R Harrold; Susan E Andrade; Becky Briesacher; Marsha A Raebel; Hassan Fouayzi; Robert A Yood; Ira S Ockene
Journal:  Am J Med       Date:  2010-01       Impact factor: 4.965

10.  Gout disease-specific quality of life and the association with gout characteristics.

Authors:  Jan D Hirsch; Robert Terkeltaub; Dinesh Khanna; Jasvinder Singh; Andrew Sarkin; Micki Shieh; Arthur Kavanaugh; Susan J Lee
Journal:  Patient Relat Outcome Meas       Date:  2010-03-01
View more
  6 in total

1.  Anti-nociceptive and anti-edematogenic effects of glibenclamide in a model of acute gouty attack in rats.

Authors:  Rosane M S dos Santos; Sara M Oliveira; Cássia R Silva; Carin Hoffmeister; Juliano Ferreira; Jamil Assreuy
Journal:  Inflamm Res       Date:  2013-03-30       Impact factor: 4.575

2.  Primary care providers' knowledge, beliefs and treatment practices for gout: results of a physician questionnaire.

Authors:  Leslie R Harrold; Kathleen M Mazor; Amarie Negron; Jessica Ogarek; Cassandra Firneno; Robert A Yood
Journal:  Rheumatology (Oxford)       Date:  2013-04-25       Impact factor: 7.580

3.  Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.

Authors:  Nicola Dalbeth; Meaghan E House; Anne Horne; Keith J Petrie; Fiona M McQueen; William J Taylor
Journal:  BMC Musculoskelet Disord       Date:  2012-09-16       Impact factor: 2.362

Review 4.  How Can We Improve Disease Education in People with Gout?

Authors:  Theodore R Fields; Adena Batterman
Journal:  Curr Rheumatol Rep       Date:  2018-03-08       Impact factor: 4.592

Review 5.  Moving the Needle: Improving the Care of the Gout Patient.

Authors:  Jon Golenbiewski; Robert T Keenan
Journal:  Rheumatol Ther       Date:  2019-03-02

6.  A Traditional Clinic Chinese Medicine Prescription Qu-Zhuo-Tong-Bi (QZTB) Alleviates Gouty Arthritis in Model Rats.

Authors:  Huiqing Lv; Jianzhi Chen; Fenfen Liu; Yan Jin; Zhenghao Xu; Chengping Wen; Jie Yu
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-06       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.